PDCD1 and neoplasm: showed that PD-1 activation on lung cancer tumor cells by its ligand PD-L1 decreased the canonical activation of signalling pathways involving AKT and MAPK, effects blocked by antibodies inhibiting the PD-1/PD-L1 axis (167).